South Carolina Medicaid and Weight-Loss GLP-1s: What Was Dropped and What Remains

No. South Carolina Medicaid removed GLP-1s for obesity from its drug list on December 31, 2025, only 14 months after it began covering them on November 1, 2024.^[1][2] As of November 2026 the state’s preferred drug list has no entry for Wegovy, Zepbound or Saxenda.^[3] Diabetes coverage did not change, and the state’s committee was told Wegovy stays covered for uses other than obesity, such as heart risk and the liver disease MASH.^[1]

When did South Carolina Medicaid stop covering Wegovy for weight loss?

The removal date in the minutes is December 31, 2025, and health plans told members the change took effect January 1, 2026.^[1][7] One plan’s member page names Wegovy and Saxenda.^[7] People who check the record may notice that the list dated January 1, 2026 still shows a weight management class with Wegovy as preferred. The next posted list, from April 1, 2026, has no Wegovy at all, and neither has any list since.^[4] The minutes are the state’s plain statement of intent, so we read the January list as a holdover, though the state has not said so.

Federal law gives the state this choice, since states may leave weight-loss agents out of Medicaid.^[12] The state’s pharmacy manual now lists “weight control products” among items not covered regardless of circumstance, and it excludes drugs used as anorexiants.^[6] We found no state document giving a reason for the reversal, or a count of members affected.

What was left after the GLP-1s were removed?

Very little, and that is the unusual part of South Carolina’s story. When coverage began in 2024, the state cited it, along with low use, as a reason to stop paying for orlistat a year later.^[2] When the GLP-1s left, orlistat did not come back: the November 2026 list names no weight-loss drug of any kind.^[3] Since the manual also excludes anorexiants, people who want an older option such as those in our phentermine comparison should expect to pay for it themselves unless the plan says otherwise.^[6] The list warns that classes it does not name may be handled differently by each plan, so a call can settle it.^[3]

Does South Carolina Medicaid still cover Wegovy for heart disease or MASH?

The committee minutes say yes, and warn that members already taking Wegovy for those uses may need a new prior authorization.^[1] Wegovy’s label does carry both: lowering the risk of major heart events for adults who already have heart disease and excess weight, and treating noncirrhotic MASH with F2 to F3 fibrosis.^[14]

What the state has not posted is the test. Its index of prior authorization criteria lists GLP-1 diabetes criteria but no document for Wegovy, and the diabetes criteria revised October 1, 2026 name only type 2 diabetes routes.^[5] Because Wegovy is off the single list, the list’s own caveat applies: fee-for-service and each plan may handle it differently.^[3] A prescriber should call the plan before writing the request and ask for the criteria in writing. Our guide to GLP-1s and fatty liver covers what the MASH trial showed.

Does South Carolina Medicaid cover Zepbound?

We found no South Carolina document that says so. Zepbound is absent from the 2026 lists we read, and the minutes’ carve-out names only Wegovy.^[1][3] That leaves the sleep apnea use, which is on the label for adults with obesity, without a published route in this state.^[15] It also does not amount to a stated refusal. Someone with a moderate to severe sleep apnea diagnosis can ask for a written decision and appeal it. For how this works nationally, see how the sleep apnea approval changes the Medicaid question.

Does South Carolina Medicaid cover Ozempic for diabetes?

Yes. Ozempic and Trulicity are the preferred injectables, while Mounjaro, generic liraglutide, exenatide, Victoza, Soliqua and Xultophy are non-preferred.^[3] All of them sit under clinical criteria that require a documented type 2 diabetes diagnosis, a failed or unsuitable trial of metformin with a 90-day claims look-back, and an A1c from the past three months.^[5] Non-preferred drugs also need a trial of the preferred ones or a reason they cannot be used.^[5] Approval runs six months at first and a year on renewal, which asks for improved A1c or fasting glucose.^[5] Trulicity is the route for children from age 10.^[5]

Does it matter which Healthy Connections plan you have?

For classes on the list, no. Fee-for-service and all the plans use the same preferred and non-preferred drugs.^[3][9] That is why changing plans will not bring weight-loss coverage back. For Wegovy’s other uses, the answer is less tidy, because Wegovy is no longer on the shared list and the state has not published shared criteria for it.^[3][5]

Members under 21 have a further argument. Federal child-health rules require Medicaid to provide necessary treatment whether or not the state plan covers it.^[13] We found no South Carolina document applying that to these drugs. A family can ask for a medical necessity review by name.

How do you appeal a denial in South Carolina?

• Plan first. People in a managed care plan are told to use its internal appeal first.^[10] Federal rules give 60 calendar days from the notice.^[11]
• State hearing. The state’s appeals page uses a 30-day window, and some notices count from the notice date, so follow the one on yours.^[10]
• Keeping benefits. You may ask for continued benefits within 10 days of the notice, though you could have to repay them if you lose.^[10]
• Speed. Standard state appeals are meant to finish within about 90 days, and you can ask for an expedited review.^[10]

Appeals have traction when the use is covered and the file is short of something. They have far less when the only diagnosis is obesity, because the drug is no longer in that benefit. Our walkthrough of prior authorization and appeals shows what to include. A prescriber should never add a diagnosis you do not have.

What are the options if you lost coverage?

Self-pay is what remains for most people. Lilly’s savings card for insured patients excludes government programs.^[16] Prices in the figures we track are $349 a month for most Wegovy pen doses from Novo Nordisk, and from $299 at the starting dose up to $449 at higher doses for Lilly’s Zepbound KwikPen or vial.^[16][17] Check each offer’s terms for limits on Medicaid members. The guide to the lowest GLP-1 prices without insurance compares them.